The Carer QALY Trap
Jason Shafrin
Senior Managing Director, Center for Healthcare Economics & Policy at FTI Consulting; Adjunct Professor, University of Southern California
The term "Carer QALY" was coined in a paper by Mott et al. (2023) and is identified as the case where "it is possible for an effective treatment that provides survival gains (with relatively little or no QOL gain) to appear less effective than the comparators when carer QOL is considered."
While the term "Carer QALY trap" is new, this issue has long been known. In fact, the patient QALY trap--that extending the life of a person with a chronic disease is less valuable than extending the life of a person without one--was identified by Ubel et al. (2000) among others. The TIlford and Tarlan (2023) editorial--citing citing Lundin and Ramsberg (2008) --uses a parable to explain the carer QALY trap as follows:
Lundin and Ramsberg portray two people on an island needing to decide whether to create a snake bite antidote that would save the life of the person after being bitten. The island snakes resided in an area with better food, and picking fruit there would increase the QoL of the two inhabitants on the island but incur the risk of being bitten while picking fruit. If one person is bitten and survives using the antidote, in the parable by Lundin and Ramsberg, the survivor would live with a very low QoL. The healthy person would then incur survivor consumption costs by having to provide for the person who survived the snake bite. The link to the carer QALY trap is straightforward; in providing for the person with the snake bite, the healthy person loses QALYs.
A similar example would be considering a treatment that would prolong the survival of a child with severe brain damage. Because QoL would be low, life extension would create few QALYs for the patient; moreover, the caregiver QoL would decline. Thus--similar to the snakebite case--there may be no net societal health gains for a life-extending treatment for brain damage.
A numerical example from Mott et al. is below.
领英推荐
The authors note that this is not just a theoretical problem:
In two recent National Institute for Health and Care Excellence (NICE) technology appraisals (TA588 and TA755), the inclusion of carer QOL in the economic models resulted in fewer QALYs being accrued with the new treatment, contributing to the treatment being deemed not cost effective. The implication was that life-extending treatments may not represent an efficient use of resources, at least in part due to the negative QALY impact that they would have on informal carers.
While caregiving for a disabled individual may decrease momentary utility--since it is both physically and emotionally hard work--carers quality of life could improve if we consider altruism effects (positive value of extending life of a loved one) or the bereavement effects (negative impact of the death) in the calculation. As an economist, I certainly rely on numerical analyses to evaluate treatment value; however, the carer QALY trap highlights that contextual considerations and qualitative information are needed to supplement the qualitative analysis whenever you are conducting health technology assessment.
Originally posted at Healthcare Economist .?
The views expressed herein are those of the author and not necessarily the views of?FTI Consulting, Inc., its management, its subsidiaries, its affiliates, or its other professionals.
Strategist for Vision Zero Cancer- mission-driven innovation in cancer
11 个月Mhm. Obviously not my field- so I expect to get slaughtered by some here anyway- but as someone at the receiving end, I *do* have an opinion. This oddly smells of 'not cost-effective at zero cost' which if anything highlights the limitations of the method- calling it a 'trap' would assume some cunning intention....? I got 2 issues with this approach: firstly, most of the carer burden is happily shifted off to the affected families anyway- loss of an income, impact on career and overall finance, mental health for your entire family, trans-generational impact due to both loosing someone close AND the financial mess- so the damage is way more extensive than this miserable extension of one year but with the convenient siloing of things, it's not that it affects drug budgets anyway, does it. So pretending that my carer QoL was just miserable in the year my husband was still alive and that *because* of the treatment he received- that frankly is just conceptual nonsense. Rather a convenient way to punish any reduction in QoL twice- seems time to move out of this pretend-we-care-about-QoL-of-anyone and move straight to cost-containment, shall we?
Experienced research and policy leader
11 个月This is not a trap and it’s not about the QALY. It’s about rational decision making and logic.? It’s important that we avoid misleading language like ‘trap’, and presenting an issue as a problem with the QALY when it is a characteristic of any internally coherent outcome measure designed for use in priority setting. There are plenty of challenges in HTA without creating artificial ones.
Principal Economist | Federal Reserve Board | Expert in Financial Regulation, Risk Management, & Consumer Finance | Skilled in Cost-Benefit Analysis & Data Science | Enhancing Markets & Promoting Financial Stability
11 个月I don't understand why this is called a trap. Isn't a treatment that saves 1/10 patients from certain death and lets them live 10 more years at full health better than one that saves the same fraction of people but lets them live five years more in poor health? These kinds of choices seem inescapable. Maybe QALY does a bad job of measuring life quality, but surely there is no escaping engaging seriously with the quality of life that our treatments allow.
Retired-Senior Manager at Providence Health Plan
11 个月Great Summary!
Managing Director and Head of the Center for Pharmacoeconomics, MEDACorp LLC
11 个月I always enjoy your summaries, Jason. Thank you for sharing. A similar phenomenon can occur when monetizing time spent caregiving and bringing in the numerator of the incremental cost-effectiveness ratio. Prolonging the life of an individual with a condition that requires caregiving, also prolongs/extends the time caregiving. If the caregiver actually prefers to prolong their time spent caregiving for the life extension of their loved one, then the traditional approaches to monetize time spent caregiving may not align with those preferences.